Abstract: Thirty-nine caudatin analogs were designed and synthesized. Their anti-hepatitis B virus (HBV) activities were evaluated in vitro. Among them, twenty-three compounds showed much better anti-HBV activity than caudatin, and eleven compounds significantly inhibited the HBV DNA replication with IC 50 values < 10 L . Interestingly, three compounds ( L ) with lower cytotoxicity. The structure-activity relationships (SARs) of these caudatin analogs were also discussed.
INTRODUCTION
Hepatitis B virus (HBV) infection remains a global health problem, which can cause liver failure, fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) [1] . Currently, therapies for HBV infection include immuno-modulators, interferons (interferon-alpha and pegylated interferon) and nucleosides/nucleotides analogues (lamivudine (3TC), adefovir dipivoxil (ADV), entecavir (ETV), telbivudine (LdT) and tenofovir-DF (TDF)), but they are unsatisfactory. For example, vaccine failure will result that millions of the HBV patients will eventually succumb to the infection sequence; application of interferons is limited for low curing rate and serious side effects (influenza-like symptoms, fatigue, myalgia, nausea, headache, etc.); nucleoside analogues result in drug resistance and high recurrence for the single target on the viral DNA polymerase [2] [3] [4] [5] . Thus, researchers are continuing to search for new anti-HBV agents.
Natural products and their derivatives by simple functional-group transformations offer many opportunities for finding novel anti-HBV agents [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . As an ongoing search for potential anti-HBV inhibitors, our latest study revealed that caudatin ( Fig. 1) from Cynanchum auriculatum (BaiShou-Wu in Chinese) exhibited potent activity inhibiting the secretion of HBsAg and HBV DNA replication and 3-O-(3, 4, 5-trimethoxy) cinnamoyl caudatin ( Fig. 1) had the novel action mechanism inhibiting HBV by interfering HBV promoters and enhancers [6] . In additional, the anti-HBV *Address correspondence to this author at the State Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, PR China; Tel: + 86 871 5223265; Fax: + 86 871 5227197; E-mail: chenjj@mail.kib.ac.cn activity largely depended on the size and character of the substituent for 3-O-substituted caudatin derivatives based on our previous report [8] . For example, introduction of nitrogen aromatic and cinnamoyl moiety at C-3 position could significantly enhance the anti-HBV activity, but substitution with diglycolyl, glutaryl, and phosphate esters led the contrary results, which indicated that the hydroxyl group at C-3 of caudatin was a good target for further chemical modification by introduction of the rational substitutions. Consequently, further modification on C-3 hydroxyl group of caudatin was conducted to gain more novel anti-HBV agents. Herein, we reported a series of caudatin derivatives modified on rings A and D at C-3, C-17, respectively. Structureactivity relationships (SARs) of these caudatin analogs with anti-HBV activity were also discussed.
RESULTS AND DISCUSSION

Chemistry
The syntheses of caudatin analogs were summarized in Scheme 1. Derivatives 1-31 were synthesized by the reaction of corresponding acids with caudatin in the presence of N, N'-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP). Compound 32 was obtained through caudatin reaction with gallic acid in the presence of diisopropyl azodicarboxylate (DIAD) and triphenylphosphine (TPP). As oxygen and sulfur heterocylic rings were effect functional groups to search potential anti-HBV activity according to previous investigation [18] [19] [20] [21] [22] , some heterocylic rings containing oxygen and sulfur atoms were introduced into the caudatin in order to obtain the active analogs. In order to further evaluate the effect of hydroxyl groups at C-3 and C-17 for biological activity, the C-3, 17 diesters (33-39) of caudatin were synthesized. All of these synthesized analogs were purified by column chromatography and their structures were characterized by spectroscopic means ( 1 H, 13 C NMR, MS and HRMS). For instance, compounds 33-39 were determined based on the expected down-field shift at C-17 (from 91.5 to 96.3-98.4) comparing to caudatin.
Biological Evaluation
These analogues were tested for their potential anti-HBV activities, including inhibiting the secretion of hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and HBV DNA replication in HepG 2.2.15 cells using tenofovir as control, and the results of their anti-HBV activity and cytotoxicity were listed in Tables 1-3 .
As shown in Table 1 , acetyl derivative 1 showed inhibitory potency to the HBV DNA replication. Compound 2 showed potent activity inhibiting both the secretion of HBsAg (IC 50 =8.25 =M), HBeAg (IC 50 =7.85 =M), and HBV DNA replication (IC 50 =5.95 =M). Compounds 3 and 4 exhibited inhibitory activity against the secretion of HBsAg and HBV DNA replication, instead of the secretion of HBeAg with the higher cytotoxicity than that of caudatin, which may be due to the unsaturated C C bond. The position of methyl group in compounds 5 and 6 could influence the activity based on the IC 50 values of the secretion of HBsAg, HBeAg and HBV DNA replication. The anti-HBV activity and cytotoxicity would be enhanced (7 vs 8, 9 vs 10) when the C=C double bond incorporated in caudatin derivatives. From the above results, it was suggested that the anti-HBV activity and cytotoxicity would be enhanced when the unsaturated C C and C=C double bond incorporation in caudatin derivatives. The anti-HBV activities of compounds 1-16 suggested that the chain length affect the anti-HBV activity of these analogs. The derivatives with eight carbons and less exhibited higher activity inhibiting the secretion of HBsAg and HBV DNA replication than caudatin, and their anti-HBV activities could be enhanced when the carbon atoms increased. Derivatives (9-16) with ten to eighteen carbon atoms showed lower anti-HBV activity and cell cytotoxicity than that of caudatin, except that compound 16 (with three C=C double bonds) was observed to possess activity against the HBV DNA replication with the IC 50 value of 87.94 =M.
Based on previous investigations that the anti-HBV agents usually contain oxygen and sulfur heterocylic rings, caudatin analogs with diverse heterocylic rings containing the oxygen and sulfur atoms were synthesized to obtain more anti-HBV agents. Most of these analogs manifested potential anti-HBV activity ( 4H-chromene-2-carbonyl group showed potent anti-HBV activity by inhibiting the secretion of HBsAg (IC 50 = 52.81 = ,), HBeAg (IC 50 = 173.51 = ), and HBV DNA replication (IC 50 = 5.69 = ). Based on these results, it could be concluded that introduction of heterocylic rings containing the oxygen and sulfur atoms could largely enhance the activity. Compound 29 with one nitro group exhibited the excellent activity against the secretion of HBsAg and HBeAg and HBV DNA replication with the IC 50 value of 56.08 = , 70.39 = and 8.23 = , respectively. The cytotoxicity of compound 30 increased when two nitro submitted in the benzoyl, which may be due to the influence of electronwithdrawing substituent on the aromatic moiety to have a higher activity while too much of these groups have a deleterious effect. Compound 31 showed better reducing the secretion of HBsAg and HBV DNA replication activity than that of caudatin, but its cytotoxicity was on the same level as caudatin. When the 3, 4, 5-trihydroxybenzoyl group was introduced into caudatin derivatives, the activity of compound 32 inhibiting HBV DNA replication increased 5 times, but the cytotoxicity was increased too. The HBsAg and HBeAg were illustrated that played the role in HBV infection and seroconversion was an important end point in the treatment of chronic hepatitis B [23] [24] [25] . The potential derivatives of caudatin inhibited not only the secretion of HBsAg and HBeAg but also the HBV DNA replication, even some of derivatives had greater activity against the secretion of HBsAg or HBeAg than that of the tenofovir (positive control, nucleotide drug), which suggested that they might had different mechanisms from the nucleoside analogs.
The effects of the functional group at C-17 for maintaining anti-HBV activity was further demonstrated by comparing the activities of 3-O-substituted derivatives with that of 3, 17-O-disubstitued derivatives. The decreased cytotoxicity of compounds (34-37, 39) proved that the free hydroxyl groups could influence the activity and cytotoxicity as shown in the Table 3 . Among of the 3, 17-O-disubstitued derivatives, only compounds 33 and 38 showed higher anti-HBV activity than cuadatin, indicating that the type of substituent groups could also influence the activity and cytotoxicity.
CONCLUSION
In summary, thirty-nine analogs of caudatin were synthesized, and evaluated their anti-HBV activity. Among them, twenty-three compounds showed greater anti-HBV activity than caudatin and eleven compounds exhibited significantly inhibitory activity of HBV DNA replication with IC 50 values under 10 = . Three compounds ( . These results demonstrated that the SARs of caudatin derivatives were summarized as (I) the anti-HBV activity and cytotoxicity would be enhanced when the unsaturated C C and C=C double bond incorporation in caudatin derivatives; (II) the activity would increase along with the increasing length of the introduced fatty chain till the carbon number of chain reached eight; (III) introduction of heterocylic rings containing the oxygen and sulfur atoms could largely enhance the activity; (IV) hydroxyl groups were important feature in maintaining antiviral activity; (V) hydroxyl group at C-3 of caudatin was a good target for further lead optimization by introduction of the rational substituent. This study provided valuable information for the designing, exploring, and developing novel anti-HBV agents to prevent HBV infection.
EXPERIMENTAL METHODS
Chemistry
1 H and 13 C NMR spectra were recorded on Bruker AM 400 MHz or Bruker DRX 500 MHz or Bruker Avance III 600 MHz spectrometers with tetramethylsilane (TMS) as the internal standard (Bruker, Bremerhaven, Germany). MS and HRMS spectra were determined on AutoSpec Premier P776 (VG, Manchester, UK) or API QSTAR Pulsar (AB, Foster City, USA) mass spectrometers. Column chromatography (CC): silica gel (200-300 mesh; Qingdao Makall Group CO., LTD; Qingdao; China). All reactions were monitored by thin-layer chromatography (TLC) on silica gel plates. Caudatin was isolated from Cynanchum auriculatum (BaiShou-Wu) and had the purity of > 95.0 %. Reagents were purchased from Alfa Aesar or J&K Scientific Ltd. Organic solvents were analytical reagent grade and purchased from Tianjin Chemical Reagent Co., Ltd. 
Synthesis of Compound 3-O-Acetylcaudatin (1) [7]
A mixture of caudatin (0.2 mmol), acetic anhydride (1.2 equiv) and DMAP (0.2 equiv) was heated in anhydrous pyridine (5.0 mL) overnight under reflux until the starting material was not observed by TLC check. The reaction mixture was diluted with EtOAc (20 mL) and washed with 5% HCl solution (20 3 mL). The organic layer was dried using Na 2 SO 4 and concentrated under reduced pressure. The residue was purified using a silica gel column to afford the pure target product. White amorphous powder, yield 86. 
General Procedure A for Preparation of Derivatives (2-31) [8]
The DCC (1.2 equiv) was added to the solution of caudatin (0.2 mmol), DMAP (0.2 equiv), and appropriate carboxylic acid (1.2 equiv) in anhydrous CH 2 Cl 2 (8 mL) at 0 °C. The resulting mixture was stirred at room temperature until the starting material was not observed by TLC. The reaction mixture was filtered, and the residue was washed with CH 2 Cl 2 (2 10 mL). Then, the CH 2 Cl 2 solution was washed with 5% HCl (3 30 mL), saturated NaHCO 3 (3 30 mL) and saturated NaCl (3 30 mL), respectively. Subsequently, the organic layer was dried by Na 2 SO 4 and concentrated to dryness under reduced pressure. At last, the residue was purified by column chromatography over the silica gel with petroleum ether/acetone (60:40 -95:5) to yield the pure target compounds.
3-O-Acryloylcaudatin (2)
White amorphous powder, yield 53. 1H, m, H-16 
3-O-(But-2-ynoyl)caudatin (4)
White amorphous powder, yield 49. 
3-O-(2-Methylpentanoyl)caudatin (5)
White amorphous powder, yield 82. 
3-O-(4-Methylpentanoyl)caudatin (6)
White amorphous powder, yield 80. 1H, s, H-6 
3-O-Octanoylcaudatin (7)
White amorphous powder, yield 78. 
3-O-(Oct-2-enoyl)caudatin (8)
Wite amorphous powder, yield 89. 
3-O-Decanoylcaudatin (9)
White amorphous powder, yield 84. 12H, overlap, 4 , 5 , 6 , 7 , 8 , 9 ), 1.40 (3H, s, CH 3 -18),  1.51-1.65 (3H, m, H-9, 3 ), 1.80-1.98 (9H, overlap, H-1, 2 1H, m, H-16 
3-O-(Dec-2-enoyl)caudatin (10)
White amorphous powder, yield 77. 2C-6 , 8 ), 31.7 (C-10 ), 31.8 (C-16), 33.1 (C-7) , 34.1 (C-2 ), 34.5 (C-15), 36.9 (C-10), 37. 15 (3H, s, CH 3 -19), 1.24-1.29 (20H, overlap, 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 ),  1.40 (3H, s, CH 3 -18), 1.52-1.65 (3H, m, H-9, 3 ), 1.81-1.98 (9H, overlap, H-1, 2, 11, 15, 16 
3-O-Stearoylcaudatin (14)
White amorphous powder, yield 50. C-9 ), 131.9 (C-16 ), 139.3 (C-5), 165.9 (C-3 ) 2C-3 , 4 
3-O-(Cyclopentanecarbonyl)caudatin (18)
White amorphous powder, yield 69. 
3-O-[(S)-tetrahydrofuran-2-carbonyl]caudatin (19)
White amorphous powder, yield 81. C-5 ), 71.3 (C-12), 73.8 (C-3), 74.1 (C-8) , 76.5 (C-2 ), 88.0 (C-14), 91.4 (C-17), 112.7 (C-2 ), 118.9 (C-6), 138.7 (C-5), 165 1H, m, H-16 
3-O-(Furan-2-carbonyl)caudatin (21)
White amorphous powder, yield 65. 
3-O-(Benzofuran-2-carbonyl)caudatin (22)
White amorphous powder, yield 57. 
